stapled peptides v phylomer peptides, page-25

Hi Tony

Given you have frequent correspondence with the company and also in that you have started this conversation with management...may I ask that you request on behalf of shareholders that the company does not wait until the next shareholder newsletter (presumably June) to update shareholders as to the status of all current deals.

My concerns are pretty obvious which are the inability to convert existing deals, inability to contract new deals and the resulting cash burn and business viability/survivability issue. Why not take the opportunity to update the market fully and hopefully alleviate concerns by producing a deal status sheet with the March quarterly 4C due in ~3 weeks? This info must be readily available? Thanks